|
Gender, M/F (%male)
|
123/93 (56.9)
|
|
Age (yrs) (mean ± SD) *
|
53.6 ± 9.0
|
|
Initial Weight (Kg) (mean ± SD)*
|
76.4 ± 14.0
|
|
BMI (Kg/m2) (mean ± SD)*
|
27.5 ± 4.7
|
|
Median Aminotrasferase levels. U/L (range)**
| |
|
Baseline Alanine aminotrasferase (ALT)
|
95 (61–165)
|
|
Baseline Aspartate aminotransferase (AST)
|
84.5 (52–123)
|
|
HCV Genotype, n (%)
|
n = 216
|
|
Genotype 2
|
12 (5.6)
|
|
Genotype 3
|
204 (94.4)
|
|
Response to previous treatment, n (%)
|
n = 216
|
|
Non-responders
|
128 (59.3)
|
|
Relapsers
|
88 (40.7)
|
|
Histological diagnosis, n (%)***
|
n = 196
|
|
Fibrosis stage 0 – 2
|
47 (24.0)
|
|
Fibrosis stage 3 – 4
|
149 (76.0)
|
|
Baseline serum HCV RNA (IU/mL), n (%)****
|
n = 155
|
|
< 800.000
|
55 (35.5)
|
|
≥ 800.000
|
100 (64.5)
|
